Market Analysis - Monthly Report - September&October, 2020 - Pharmaceutical
ECHEMI monthly report of Pharmaceutical
in September&October 2020

Azithromycin
https://www.echemi.com/cms/128344.html
Remdesivir
https://www.echemi.com/cms/128345.html
Florfenicol
https://www.echemi.com/cms/128346.html
Oseltamivir Phosphate Product&Shikimic Acid
2026-09-05
Trade Alert
Delivering the latest product trends and industry news straight to your inbox.
(We'll never share your email address with a third-party.)
Related News
-
Egyptian Pharmaceutical Market Research
-
CPHI China 2023 | At the Heart of Pharma
-
A Guide Into What the Pharmaceutical Use of Hexamine Is
-
In line with the 8201, Hengrui Pharmaceutical plans the HER2 ADC in this way
-
$50 billion in products were 'returned' to rationalize those blockbuster BD deals
-
Tronsound long-acting IL-36R antibody obtained FDA clinical IND
-
Dapagliflozin is approved in the EU for the treatment of symptomatic chronic heart failure
-
The FDA accepted Zuranolone's NDA application and granted it priority review rights for the treatment of MDD and PDD
-
Asia Hong Pharma announced that it has co-developed an innovative tumor therapy based on AI+RNA technology route with ReviR
-
Ribo Biologics announced that the world's first FIH application for a siRNA drug targeting FXI has been successfully approved by HREC in Australia
Recommend Reading
-
On July 13, China's propylene oxide market showed a significant upward trend
-
Upward Momentum Fades, Formic Acid Prices Return to Stable Operation
-
Geopolitical Supply Concerns on July 13 Boost Ethylene Glycol Prices Significantly in China
-
U.S.-Iran Conflict Reignites, International Crude Oil Surges Over 9% in a Single Day
-
Cost-side Speculative Sentiment Rises, PP Strongly Rebounds in Early July
-
Premium Global Chemical Sourcing Requests (9-12Apr, 2026)
-
U.S. Exempts Critical Chemical Manufacturers from Emissions Rules for Two Years
-
China Releases 15th Five-Year Carbon-Peaking Action Plan, Pushing Coal Chemicals into a Mandatory Low-Carbon Upgrade Cycle
-
FDA Slows Two Natural Color Approvals, but the Additive Shift Is Still Moving
-
Premium Global Chemical Sourcing Requests (6-8 Apr, 2026)